Repoxegen Therapeutics
June 16, 2025
Company Presentation
Ophthalmology
Repoxegen Therapeutics (a JLabs incubated company) is developing a groundbreaking oral drug that targets a key biochemical path-way enzyme in fatty acid metabolism involved in neuro-inflammation, an important event in the evolution of neurodegenerative and retinal degenerative diseases in patients. The drug compound is in development candidate stage (and backups), with demonstrated efficacy in animal models, short term tox, high therapeutic index, and basic pharmacological profile complete, ready for IND enabling studies.
We are focusing investor funds on developing the candidate compound for diabetic retinopathy due to the large treatment gap for nonproliferative diabetic retinopathy and because the path to human proof-of-concept will be quicker (150 patients for phII) and outcomes are objectively determined by measurements in the eye by OCT, giving the development path a much lower risk than neurodegenerative indications.
.png)
Company HQ City:
Los Altos Hills
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2023
Lead Product in Development:
RPX101A
CEO
RObert Molinari
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
1
When you expect your next catalyst update?
IND filing, POC in Phase II clinical study
What is your next catalyst (value inflection) update?
12-14 months from funding
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}